Movatterモバイル変換


[0]ホーム

URL:


CA2218281C - Method and apparatus for noninvasively determining hematocrit - Google Patents

Method and apparatus for noninvasively determining hematocrit
Download PDF

Info

Publication number
CA2218281C
CA2218281CCA002218281ACA2218281ACA2218281CCA 2218281 CCA2218281 CCA 2218281CCA 002218281 ACA002218281 ACA 002218281ACA 2218281 ACA2218281 ACA 2218281ACA 2218281 CCA2218281 CCA 2218281C
Authority
CA
Canada
Prior art keywords
signals
blood
current
voltage
quadrature
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002218281A
Other languages
French (fr)
Other versions
CA2218281A1 (en
Inventor
Paul W. Ruben
Allan L. Kaminsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Microcor Inc
Original Assignee
Microcor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/425,404external-prioritypatent/US5526808A/en
Priority claimed from US08/602,700external-prioritypatent/US5642734A/en
Application filed by Microcor IncfiledCriticalMicrocor Inc
Publication of CA2218281A1publicationCriticalpatent/CA2218281A1/en
Application grantedgrantedCritical
Publication of CA2218281CpublicationCriticalpatent/CA2218281C/en
Anticipated expirationlegal-statusCritical
Expired - Fee Relatedlegal-statusCriticalCurrent

Links

Classifications

Landscapes

Abstract

This invention is a method and apparatus for non-invasiveness in determining hematocrit, utilizing the frequency dependent electrical impedance characteristics of whole blood by electrically stimulating a patient body portion containing a vascular compartment with a current source over a range of frequencies. A hematocrit measurement system includes a signal generator and demodulator [SGD] (34) that sends an applied signal to an electrode pod (36) that applies a current to a limb of a patient. The electrode pod (36) receives resulting measured voltage signals and provides them to the SGD. The SGD provides to a personal computer [PC] (42) signals indicative of the current passing through the limb of the patient and the resulting voltage. The voltage and current may be measured for various frequencies over, for example, a range from about 10 kHz to about 10 MHz. The electrical impedance from the blood alone is isolated from the total limb impedance from the blood, tissue, bone, etc. by determining the difference between measurement at different blood volumes. The hematocrit is determined by the PC based on inphase and quadrature data provided by the SGD. A neural network (52) may be useful in determining the hematocrit from the blood impedance patterns.

Description

METHOD AND APPARATUS FOR NONINVASIVELY
DETFRn~NING HEMATOCRIT
' S BACKGROUND OF THE INVENTION
Field of the Invention: The present invention relates generally to determination of the Packed Cell Volume or relative volume percent of erythrocytes (red blood corpuscles), also known as the hematocrit, of whole blood, and more specifically to a method and apparatus for making such determination noninvasively through coherent techniques.
State of the Art: Hematocrit is traditionally obtained by acquiring a patient blood sample from a vein via a syringe, or by use of a capillary tube from a finger stick, or puncture. The blood, contained in an elongated vessel, is then centrifuged and the height percentage of the column of blood in the vessel which is solid represents the hematocrit.
More recently, hematocrit has been obtained by the use of elaborate and expensive cell counting laboratory instruments which are also used to provide differentiations of white blood cells, platelets, etc. However, as with the centrifuge method, the blood must be invasively removed from the patient for analysis.
In the course of routine medical procedures, such as the daily blood work performed in hospitals, the necessity of obtaining blood samples from patients and then centrifuging or otherwise analyzing the drawn blood presents no great inconvenience, as the volume of samples is large (warranting expensive automated equipment) and the time delay in obtaining results from a laboratory is generally acceptable. However, in catastrophic situations such as are encountered in the emergency rooms and shock trauma units, as well as in the course of surgical procedures wherein blood loss is probable, the hematocrit determination apparatus and methodology of the prior art are markedly deficient.
In the foregoing environments, there may be no time to draw blood, and in fact it may be impossible to identify a vein from which to draw it. Drawing blood intermittently during surgical procedures is inconvenient if not impractical, and analyzing periodic samples is time and labor intensive. Moreover, hematocrit may vary and drop at such an accelerated rate from unobserved blood loss that by the WO 96!32883 PCT/US96/04547
-2-time the emergency or surgical personnel are belatedly made aware of a problem by laboratory personnel, the patient may be in acute difficulty or even deceased.
It has been proposed to measure hematocrit noninvasively, as noted in "Noninvasive Measurement of Hematocrit by Electrical Admittance Plethysmography Technique," TEES Transactions of Biomedical Engineering, Vol.
BME-27, No. 3, March 1980 pp. 156-161. However, the methodology described in the foregoing article involves submerging an extremity, such as a finger, in an electrolyte (NaCI solution) and varying the electrolyte concentration to compensate for pulsatile electrical admittance variations by matching the electrolyte resistivity to that of the blood in the extremity; the resistivity of the electrolyte is then determined in a resistivity cell, and converted to a hematocrit value via a nonlinear least-squares regression calibration curve generated by matching centrifuged hematocrit for various erythrocyte concentrations to resistivity data previously taken directly from blood resistivity measurements of the same specimens. Aside from being unwieldy to employ in an emergency or operating room environment, to the inventors' knowledge the technique as described in the referenced article has never been followed up or verified by further research, or employed in practice.
A measurement technique termed "impedance plethysmography," or using impedance techniques to obtain a waveform, is conceptually rooted in biomedical antiquity. Medical literature abounds with vascular studies, respiration studies and attempts to determine cardiac output (the actual volume of blood flowing from the heart) by impedance techniques. None of these techniques has been proven to work particularly well, although there have been attempts at commercial instruments based on the concept. A variant of impedance plethysmography, however, electrically models intracellular as well as an extracellular tissue components and employs a comparison of measurements of tissue impedance responsive to applied electrical currents at two frequencies to quantify the intracellular and extracellular tissue components. While not directly related to the problem solved by the present invention, the electrical tissue model is useful to an understanding thereof.
In recent years, a technique known as pulse oximetry has been employed to measure blood oxygenation during induction of general anesthesia. While pulse oximetry does not provide an hematocrit indication, one may consider it helpful to an understanding of the method and apparatus of the present invention. Pulse i~
3 PCTIUS96/04547 oximetry relies upon the fact that the light absorbance of oxygenated hemoglobin and that of reduced hemoglobin differ at two wavelengths of light (generally red and near infrared) employed in an oximeter, and that the light absorbances at both frequencies have a pulsatile component which is attributable to the fluctuating volume of arterial blood in the patient body portion disposed between the light source and the detector of the oximeter. The pulsatile or AC absorbance response component attributable to pulsating arterial blood is determined for each wavelength, as is the baseline or DC component which represents the tissue bed absorbances, including venous blood, capillary blood, and nonpulsatile arterial blood. The AC components are then divided by their respective DC components to obtain an absorbance that is independent of the incident light intensity, and the results divided to produce a ratio which may be empirically related to Sa02, or oxygen saturation of the patient's blood. An excellent discussion of pulse oximetry may be found in "Pulse Oximetry," by K.K. Tremper et al., Anesthesioloev, Vol.
70, No. 1 (1989) pp. 98-108.
SUMMARY OF THE INVENTION
The present invention provides a method and apparatus for noninvasive hematocrit determination. In practicing the present invention, impedance of blood is measured via application of stimulation and sensor electrodes to a portion of the body that contains a vascular compartment of arteries, capillaries, and veins.
For the sake of convenience, the electrodes are usually applied to a forger. The stimulation electrodes are driven with an alternating voltage over a range of frequencies.
In a preferred embodiment of the invention, the sensed voltage signals are amplified by a high input impedance voltage detector, converted to the digital domain by an analog-to-digital converter, and then demodulated via mixers into two complex waveforms, one representative of the stimulation current and another representative of the sense voltage at a selected frequency. The waveforms are processed by a microcomputer to determine the tissue impedance scan indicia.
Then, the blood volume is altered and another tissue impedance scan is made.
In a preferred embodiment, a pressure cuff is used to alter the blood volume. Two tissue scans, one at one blood volume and one at another blood volume, are used to m ~.rttu,~ ~ a ~y~ ~r i~~o determine a blood impedance scan. The impedance of the whole blood is separated from the total impedance through a parallel model. The whole blood impedance indicia is correlated to hematocrit by recognizing patterns in the blood impedance scan. It is also possible and contemplated as part of the invention to determine hematocrit using the preferred embodiment of the invention by analysing the phase shift pattern with a neural network.
The invention for which protection is sought is defrned in the claims as filed or later added or amended. If a limitation that is described or :.hown irt the:
specification or drawings is not included zr1 a claixrt, the claim should not be interpreted to include the limitation.
l3ItIHF' bBSC'.RIPTION (JF Tf~i~ ~k..AWINC~S ' The present invention will be more fully understood by one of ordinary skill in the art through a review of the following detailed description of the preferred embodiments in conjunction with the accornpanyiutg drawings, wherein FIG. lA comprises a circuit schematic for a first-order electrical model of whole blood in a large vessel;
FIG. LB comprises a schematic representation of fluid and membrane cells in a Large vessel corresponding to the eh:ctrical model of kZG. lA;
~ FIG. 2A comprises a circuit schematic for a first-order electrical model of whole blood in a small vessel;
FTG. 2B comprises a schematic representation csf fluid auui membrane culls in a small vessel corresponding to the electrical model of FIG. 2A;
FTG. 3A shows a representation of the total impedance in a limb at a low blood volume;
FIG. 3B shows a representation of the total impedance in a limb at high blood volume;
F~TG. 4 corttpr-ises a block diagram schematic of a preferred embodiment of a system of the present invention;
FIG. 5A comprises a bottom plan view of a limb to which electrodes a:e applied;
FIG. 5B comprises a side view of the limb of FIG. 5A;
AMENDED St~EET

_5_ FIG. 6 comprises a more detailed block diagram schematic of the electrode pod of the system of FIG. 4;
FIG. 7 comprises a schematic representation of a wireless version of the signal generator and demodulator and electrode pod of FIG. 4;
FIG. 8 comprises a more detailed block diagram schematic of the signal generator and demodulator of FIG. 4;
FIG. 9 comprises a more detailed block diagram schematic of the air pump, solenoids, and pressure cuff of FIG. 4;
FIG. 10 comprises a more detailed schematic of the frequency generator of FIG. 4;
FIG. 11 comprises a combined diagram and schematic of a two-frequency embodiment of the present invention, with electrodes applied to a patient extremity;
FIG. 12 comprises a schematic of an embodiment of a constant current source as employed in the embodiment of FIG. 11;
FIG. 13 comprises a schematic of an embodiment of an AM detector as employed in the embodiment of FIG. 11;
FIG. 14 comprises a schematic of an embodiment of an A/D converter as employed in the embodiment of FIG. 11;
FIG. 15 comprises a graphic, not-to-scale depiction of an analog voltage signal representative of those measured in practicing the present invention showing the relatively small pulsatile component of the signal above the signal baseline; and FIG. 16 comprises a circuit schematic for a first-order electrical approximation of the impedance of a whole blood in a pulsatile vascular compartment in combination with that of the surrounding tissue in which the compartment is located.
DETAILED DESCRIPTION OF THE ILLUSTRATED EMBODIMENTS
A. Multi-Frequency Embodiments 1. Basic Electrical Models FIG. 1A is an electrical circuit model that represents an approximation of the behavior of whole blood in a large vessel when subjected to an alternating electrical current I. Resistor 10 in circuit path 12 represents the resistance R$E of the extracellular or plasma component. A capacitor 16 and resistor 18 in a parallel R'O 96/32883 PC'T/US96/04547 circuit path 14 represent the capacitance CB~ of the cell membrance and the resistance RBI of intercellular fluid of the erythrocyte or red blood corpuscles. At low frequencies (such as 50 kHz), the impedance of whole blood (fig= that of both , paths 12 and 14) is attributable primarily to the extracellular blood component circuit path 12, while at higher frequencies (for example, 1 MHz), the capacitive nature of the cell membrane of the red blood corpuscles results in a more significant impedance contribution from circuit path 14, reducing the magnitude of the whole blood impedance.
FIG. 1B illustrates a large vessel 20 containing many red blood cells 22 in plasma 24. As can be seen, there is a current path through plasma 24, even at low frequencies.
FIG. 2A is an electrical circuit model that represents an approximation of the behavior of whole blood in a small vessel when subjected to an alternating electrical current I. FIG. 2B illustrates a small vessel 26 in which cells 22 are about as wide as vessel 26 preventing a plasma path between cells 22 and the wall of vessel 26.
In such a case, the path for current I is through a capacitance CB~, in series with resistances RBI and RBE. Accordingly, the impedance of and the amount of current flowing through vessel 26 changes as the frequency of current I increases.
While the ratio of small vessels to large vessels is not known, it is believed that the effect of small vessels may be significant in the overall limb impedance. (There are some vessels that are slightly or somewhat larger than a small vessel and allow a small path around the cells.) It is understood that in the circuits of FIGS. 1A and 2A, the maximum phase shift in impedance occurs when the frequency of current I is f = 1/(R5 CB~
2~r), where RS is RBI in the case of large vessels and RS is RBI + RBE in the case of small vessels. It has been found that the maximum phase shift of blood occurs at about 1.6 MHz in large vessels. As described below, that maximum phase shift is used in determining the hematocrit. The large vessel model predominates in the blood impedance measurements. However, it is believed that the contribution of small vessels should not be ignored and that the maximum phase shift of the small vessels will occur at below 1.6 MHz. It is believed that the effect of the small vessels is reflected in the values throughout the spectrum.

_'7_ However, when current is passed through a Limb, such as is described below, the current passes not only through blood, but also through tissue, bone, etc.
The impedance of the blood may be separated from the total limb impedance through a procedure described below. In brief, in FIG. 3A, the impedance ZU
represents the total lamb impedance when blood flow through the limb is unrestricted. In FIG. 3B, the blood flow through the limb is restricted and ZB
represents the impedance of the additional blood accumulated as a result of the restriction. The total limb impedance during the restricted state is ZR. The total impedance ZU and ZR may be calculated, and ZB = (ZU x Z~/(ZU - Z~.
Therefore, the contribution of portions of the limb other than the blood does not have to determined.
2. stem Overview Referring to FIG. 4, a hematocrit measurement system 30 includes a signal generator and demodulator (SGD) 34 that sends a signal to an electrode pod 36 through conductor 38 and receives measured signals from electrode pod 36 through conductor 40. SGD 34 provides to a personal computer (PC) 42 through conductors 32 and an RS-232 port, signals indicative of the current passing through the limb of a patient and the resulting voltage. The voltage and current may be measured for various frequencies over, for example, a range from 10 kHz to 10 MHz.
The impedance from the blood alone is isolated from the total limb impedance from the blood, muscle, bone, etc. by measuring the limb impedance of different blood volumes. As described below, an air pump, solenoid(s), and pressure cuff 28 may be used to cause a change in blood volume in the limb.
PC 42 determines the hematocrit. The hematocrit may be determined from the signals from SGD 34 alone, or in combination with various other data regarding the particular patient such as age, sex, weight, temperature, illnesses, etc.
, or regarding patients in general. In this regard, as described below, a neural network may be useful. A neural network may be executed in PC 42 or in a separate computer 52, shown in dashed lines.
3. Electrode Pod and Electrodes Referring to FIGS. 4 and SA and SB, electrode pod 36 provides an alternating electrical current signal to a limb 44 (such as a forger having a forger nail 46) of a patient through electrodes 48A and 48B. (Fig. 5A shows the underside ta-~~~J ~. :: mu v I~~D
g_ of the two fingers next to the thumb of a left hand.) The resulting voltage drop across Iimb 44 is measured through electrodes SOA and 50B, The voltage between electrodes 48A and 48B may be about three volts. Electrodes =l$A, 4f3B, 50A, and 50B may be standard, commercially ;available electrodes.
Electrodes 4$A, 4$B, 50A, and 50B may be conveniently held in place through a piece of tape 54 that covers both the electrodes and a portion of limb 44.
however, tape 54 preferably does not restrict blood flow. Tape 54 may extend to 314 around the circumference of limb 44. In addition to holding the electrodc:.s in place, tape ~4 stiffens limb 44 which makes the measurement procedures more IO controlled. A splint or nnylar may also be used.
Referring to FTG. 6, elecarode pod 36 includes a 50 ohrn termination buffer 60 that receives a sine signal having frequency c,r on conductor 38 from SGD
34. A
sense resistor 64 is connected in series between butter 60 and a conductor 66A, to which electrode 48A is connected.
Electrodes 48A, 48B, SOA, and SOB are connected to electrode pod 36 through conductors 66A, 66B, 70A, and 70B, which are preferably as short as possible. Alternatively, wireless eommurucation could be used as shown in FIG.
7, which includes transmitters '16A, 768, and 76(_'., and receivers 7$A, 78B, and 7RC.
Wireless communication may be particularly useful in an operating room environntem.
Referring again to FIG. 6, an instmmentatian amplifier fib provides to conductor 72, a signal A, sin(;~t ~- B;} indicative of the voltage drop across resistor 64, where "A," is the amplitude, and 81 is a phase difference with respect to an original signal sinmt, described below. Instrumentation amplifier 6S
provides a high input impedance, and rejects the common mode voltage at conductor 66A
wlu'tle amplifying the voltage drop across resistor 64. Tnstn3mentation <implitier 68 may comprise three operational amplifiers in a well known configuration.
An instrumentation arnplitier 74 provides to a conductor 78, a signal Ai sin{cat + Qz) that is indicative of the voltage between electrodCS 50A and SUB, where "A~" is the amplitude, and 0= r; a phase with respect co the or-igonal Signal, sinc~t. ~I'tm difference in .phase between fl, and &2 is caused try ttie elccirical capacitance in limb 44 between electrodes 48A and SOB, and differences in the speed and phase response of the instmmentation amplifiers ti8 anii ~~t.
A~~Er;~EL~ SHEET

fr-~r,,liJ~ ~. v I~U v 1J~0 _g_ Accordingly, instrumentation amplifrcrs 68 and 74 should be chosen and constructed to mirrimi.ze differences in their phase responses. The differencrs irr speed and phase response of amplifiers 68 and 74 is calibrated out of the equipment using a dummy load. Thereafter, PC 42 stores the calibration information and subtracts out any differences.
Instrumentation amplifier 74 rejects the common mode voltage between conductors 66B and '70B and amplifies the differential voltage between conductors 70A and 708. Instrumentation amplifier 'l4 may comprise three operational amplifiers in a well known co~guration.
An IZF switch 80 passes either the signal on eonductar 72 ox the signal on conductor 78 to conductor 40, under the control of a signal on c:onductar 84, 1.2F' switch 80 may twitch at a rate of 110 ( =2 X 55} times per second.
4. Signal Generator and Demodulator SGD) Referring to 1~IG. b, SCiD 34 produces the signal on conductor i8 and demodulates and filters the aignals on conductor 40. SC7D 34 may include a microprocessor 94 with an embedded EPRI'~M, suc#r as an H~6805.
Microprocessor 94 provides control signals to the various components of SGD 34 to RF switch $0 through conductor 84, <rnd to solenoids of air pump, solenoids, and pressure Cuff 28, through corrducac>rs SSA, S8B, and 8$(~, as described in connection with FxG. 9, below. Microprocessor 94 also communicates with PC 42 through conductors 32.
A frequency generator 100 produces a digital sine signal I~GS~,, shown in equation (1} below, to conductors 96:
FGSQ., = sinwt ( I > >
where the amplitude is assumed to be unitary. From conductors 9fi, the signal 5inwt is provided to mixer and filter 104, and to a DAC 110. The analog sine signal from DAC 110 is provided through a buffer 112 to conductor 38. ~1'lre frequency of p'Gs~., is controlled by a frequc.ney contzol word provided by PCB' ~l2 tca Frequency generator 100.
F>~etluency generator 100 also laroduces ii digital cosine sitrot F~t::T~,_,,s shown in equation (2) below, to conductors 98:
FG~-os = C05c..~t (2), . ., ~. . ~ ..
P, . ,. .. . .

WO 96/32883 PC'T/US96/04547 where the amplitude is assumed to be unitary. Of course, coswt is 90 degrees out of phase with sinwt. From conductors 98, the signal coswt is provided to mixer and filter 106.
The signals from electrode pod 36 on conductor 40 are received by a low pass filter 116 through a buffer 118. Low pass filter 116 removes harmonic .
frequency components or abasing. The 22 MHz value was chosen to allow tissue impedance measurements with a sinwt at as high as 20 MHz. However, the analog electronics may have difficulties maintaining the required phase tolerance above about 10 MHz. With the 10 MHz upper limit, low pass filter 116 may have a lower cut off frequency. The filtered signals from low pass filter 116 are converted to digital signals through ADC 120, from which they are passed to mixer and filters 104 and 106.
DAC 110, ADC 120, and frequency generator 100 may be clocked at 60 MHz. However, if the maximum frequency of sinwt generated by frequency generator 100 is 10 MHz, then DAC 110, ADC 120, and frequency generator 100 may be clocked at, for example, 30 MHz.
Measured current indicating signals M~ are provided by ADC 120 to conductors 90. Signals M~ originate from conductor 72 in FIG. 6 and are processed through 1tF switch 80, buffer 118, low pass filter 116, and ADC 120.
Signals M~ are shown in equation (3), below:
M~ = G A1 sin(wt + 61 + ~) (3) where A1 and 91 are the amplitude and phase of the signal at conductor 72, and G
and ~ are the gain and phase shift caused by buffer 118, low pass filter 116, and ADC 120.
Measured voltage indicating signals M~ are also provided by ADC 120 to conductors 90. Signals M~ originate from conductor 78 in FIG. 6 and are processed through 1RF switch 80, buffer 118, low pass filter 116, and ADC 120.
Signals M~ are shown in equation (4), below: ' M~ = G AZ sin(wt + 6z + ø) (4) where AZ and 62 are the amplitude and phase of the signal at conductor 78, and G
and ~ are the gain and phase shift caused by buffer 118, low pass filter 116, and ADC 120. Of course, signals M~ and M~ are merely examples of current _ indicating signals and voltage indicating signals, and other circuitry than is illustrated may be used to produce suitable current and voltage indicating signals.
In mixer and filter 104, a multiplier 124 multiplies sinwt on conductors 96 with the output of ADC 120. When RF switch 80 passes the signal on conductor . 5 72, the output of multiplier 124 is the product P~ (current inphase), shown in equation (5), below:
P~ = G A1 sin(wt + 91 + ~) X sinwt _ ((G Al/2) cos (81 + ~)) - ((G Al/2) sin(2wt + 91 + ~)) (5), where G, Al, 81, and ~ are defined in connection with equation (3). Mixer and filter 104 is illustrative of mixer and filter 106.
A 60 Hz digital lowpass filter 128 filters out the ((G A,/2) sin(2wt + 8, +
ø)) component as well as various noise, leaving only the DC component, ((G
Al/2) cos (B1 + ~)). The signal ((G Ai/2) cos (91 + ~)) is applied to conductors 134 and is referred to as CI, where "C" represents the current between electrodes 48A
and 48B, and "I" stands for "in phase." Digital lowpass filter 128 may be constructed of multipliers and adders performing convolution in a well known manner.
When RF switch 80 passes the signal on conductor 78, the output of multiplier 124 is the product PEI (voltage inphase), shown in equation (6), below:
PvI = G A2 sin(wt + 62 + ~) X sinwt = ((G AZ/2) cos (82 + ~)) - ((G A2/2) sin(2wt + 92 + ~)) (6), where G, A2, 82, and ~ are defined in connection with equation (4).
60 Hz digital lowpass filter 128 filters out the ((G A2/2) sin(2wt + 82 + ~)) component as well as various noise, leaving only the DC component, ((G A2/2) cos (62 + ~)). The signal ((G AZ/2) cos (62 + ~)) is applied to conductors 134 and is referred to as VI, where "V" represents the current between electrodes SOA and SOB, and "I" stands for "in phase."
Mixing an original and modified signal to obtain amplitude and phase information is a "coherent" technique.
In mixer and filter 106, a multiplier (not shown) multiplies coswt on conductors 98 with the output of ADC 120. When RF switch 80 passes the signal on conductor 72, the output of multiplier 124 is the product P~Q (current quadrature), shown in equation (7), below:

PcQ = G A1 sin(wt + 61 + ~) X coswt _ ((G Al/2) sin (91 + ~)) + ((G Al/2) sin(2wt + 91 + c~)) where G, Al, 61, and ~ are defined in connection with equation (3). Note that the term quadrature derives from the cosine signal being 90 degrees out of phase with the sine signal. .
A 60 Hz digital lowpass filter 128 filters out the ((G Al/2) sin(2wt + 61 +
~)) component as well as various noise, leaving only the DC component, ((G
Al/2) sin (91 + ø)). The signal ((G A,/2) sin (6, + ~)) is applied to conductors 136 and is referred to as CQ, where "C" represents the current between electrodes 48A
and 48B, and "Q" stands for "quadrature. "
When RF switch 80 passes the signal on conductor 78, the output of multiplier 124 is the product P~Q (voltage quadrature), shown in equation (8), below:
P~Q = G AZ sin(wt + BZ + ~) X sinwt = ((G A2/2) cos (62 + ~)) - ((G A2/2) sin(2wt + 82 + ~)) (g), where G, A2, 9z, and ~ are defined in connection with equation (4).
60 Hz digital lowpass filter 128 filters out the ((G AZ/2) sin(2wt + 82 + ~)) component as well as various noise, leaving only the DC component, ((G .A2/2) sin (92 + ~)). The signal ((G Az/2) sin (82 + ~)) is applied to conductors 136 and is referred to as VQ, where "V" represents the voltage between electrodes SOA and SOB, and "Q" stands for "quadrature."
Signals CI and CQ provide information regarding the amplitude and phase of the current between electrodes 48A and 48B. Signals VI and VQ provide information regarding the amplitude and phase of the voltage electrodes SOA
and SOB. Signals V and C are complex i.e., they have inphase components VI and CI
and quadrature components VQ and CQ).
The inphase and quadrature impedance waveforms VI, VQ, CI, and CQ are sent to a computer, such as PC 42 where the complex impedance may be calculated -at a 55 sample/second rate.
5. Computations in the PC
The signals VI, VQ, CI, and CQ may be analyzed as follows.
The magnitude CM,,a of the current components is determined through equation (9), below:

~:-~;-:tij1 G ,l E~~U Y I~~O

CM,,,c = (Ci2 + CQ')'" (g)~
where C, and CQ are the signals on conductors 134 :u~d 136 from mixer and filters 104 and 106.
The phase C~ of the current components is determined through equation (I0), below:
C~ = tan-1 (CQ/C~ (10).
T'he magnitude V"~,,,~ of the voltage components is determined through equation (11), below:
VHrwo =~ (Vc'- -+- VQ2)''' (11}~
where V, and V~ are the signals on conductors 134 and 13fi from mixer and filters 104 and 106.
The phase V,~ of the voltage components is determined through equation (12), below:
V~ = t~-1 ('yQ/~t~ (12).
The impedance Z is the ratio of complex numbers V and C.
The magnitude Z,,.u,G component of the impedance is determined thraugh equation (13), below:
LMno .~' VM,,~,lCrt~,a = GA,IGA~ = AZ/Al (13), where Vi"~,~, and Coo are determined according to eqi~atians (11) and (9).
The phase component of the i~mpedaunce is determined though equation (14), below:
Zo = V~ - Co = (0~ + ~) -- (8, + c~) =_ (B~ - B,) (14), where V~ and C~ are determined according to equations (12) and (10).
The impedance from the blood atone is isolated from the total impedance from the blood, tissue, bone, etc. This isolation may he performed as follows.
At each frequency in a scan, the limb i.rrEpedance is determused by calculating V" VQ, C~, and C,~ when blood flow through Iimb 44 is unrestricted and, therefore, the limb has a normal or unrestricted blood volume. Then, another scan is performed over the sarr~e frequencies when blood flow through limb :14 is restricted and, therefore, the Limb has a restricted blood volume (which r»ay be higher ~~r lower than the unrestricted blood volume). :~Zethods of restriction are ~3iscussed below.
FIGS. 3A and 3$ illustrate the situation in which restriction causes an increase in blood volume. The total limb impedance at lower blood volume when J1-Cli/[,f~ G U IWU 11 1~~0 Lhe limb is unrestricted is ZU, illustrated in FIG. 3A. The total limb impedance at higher blood volume when the limb is restricted is ZR, illu~~mted in FIG. 3B.
Impedance Z~ is the equivalent to impedance Zv 1n parallel with the impedance ZB, where Z~ is the blood present at higher volume that is not present at tower volume.
(This model assumes that the extra blood has the same hematocrit as all other blood passing through the limb.) Impedance Z~ is calculated through equation {15), below zR = (ZB x Z~)!(ZB + Zu) (I5}.
Both ZR and ZU can be measured and from them Z~ can. be computed. Solving for impedance Zs in equation (15) yields equation (1b), below:
ZB = (ZU x Z~I(ZU - Z~ (16), for the case irr which restriction causes an incri;~ase in blood volume.
In the case ire which restritction causes a decrease in blood volume, ZU is equivalent to ZR in parallel with Z~, where Z~ is tire blood present at higher volume that is nvt present at lower volume. Then, impedance Zk is calculatul through equation (17), below:
ZU - (Z$ x Z,~!(Z~ + Z~ (17).
Both ZR and Z" can be measured and from them Z,~ can be computed. Solving for ixrrpedance ZB in equation (17) yields equation (18), below:
Za = (Lu x G~I(Zx ~ zu) {18)~
'r for the case in which restriction causes a decrease in blood volurne.
Although blood impedance ZH includes both a nragr>itude and phase, the phase appears to be the stronger indicator of hematocrit.. However, both phase and magnitude of ZB may be used izt pattern analysis in a neural network.
'1<'tte processes of determining ZB are repeated for various frequencies over a range from about 10 kHz to about IU lull. 'Various steps may be used. In the current embodiment, there may be from 3 steps per octave to 10 steps per octave, where octaves are 10 l~Hz, z0 kHz, :;4 kHz, 8a ldlz, 160 kliz, e.tc_ There are advantages and disadvantages in having a laxge versus a small nr!tnber of steps. A large number of steps may be used to average crut arterial pulsation noise, but takes more time and, therefore, there is a greater risk that the blood volume will undesirably and unpredictably ctlange over tinge with a longer measurement.

R'O 96/32883 PCT/US96104547 It has been found by the inventors that the phase change increases (as a negative number) from about 10 kHz to in the region of 1.6 MHz and then begins to decrease (although there may be an inflection point at well below 1.6 MHz).
(de Vries, P.M.J.M., et al., "Implications of the dielectrical behavior of human blood for continuous on-line measurement of hematocrit", Med. Biol. Fng. & Comput.
31, 445-448 (1993) notes a 1.6 MHz maximum phase.) However, it is expected that the maximum phase change will vary depending on various factors.
Therefore, a neural network approach is proposed.
6. Preferred Procedures The following procedures may be used. A "scan" refers to the process of applying signals of various frequencies in steps between a lower and upper frequency limit to electrode 48A. As described above, this creates a current between electrodes 48A and 48B, and a voltage between electrodes SOA and SOB.
It takes about one 55th of a second to gather VI, VQ, CI, and CQ signals at each frequency. Digital filter 128 requires about 9 milliseconds to achieve the desired 60 Hz bandwidth. Accordingly, digital filter 128 processes P~ for 9 milliseconds and then processes P~I for 9 milliseconds at one frequency. The processes is then repeated for 9 milliseconds for P~ and then 9 milliseconds for P~ at another frequency. The corresponding digital filter in mixer and filter 106 similarly processes P~Q and PVQ.
In a preferred embodiment, the software is written so that the lower and upper frequency limits are 10 kHz and 10 MHz, and the number of steps between the lower and upper limits are between 11 and 101 frequencies. If 101 frequencies are chosen, it takes about 1.8 seconds (= 101/55) to complete a scan.
A "repetition" refers to the number of "scans" that are performed in quick succession before changing the blood volume. In a preferred embodiment, the software is written so there may be between 1 and 10 repetitions. The reason to perform multiple repetitions is as follows. Arterial pulsations cause a small alternating fluctuation in blood volume. The pulsations can affect the phase.
If multiple repetitions are made, the variations in phase caused by arterial pulsations can be averaged and the effect reduced.
A "measurement" refers to the completion of a specified number of scan repetitions at a particular blood volume. In a preferred embodiment, the software is -~ ~. .~.~ ~ v m a v 15 ~ a _1h_ written to make any number of measurements up to 25. For ex,nnple, a first measurement is at unrestricted blood volume. A second measurement is at restricted blood volume. A third measurement may be at the unrestricted blood volume or some other blood volume, and so forth. Depending on the restrictive pressure (such as from a cuff) and the vasculax circulation, it can take between about IO seconds to 45 seconds for blood volume of limb 44. to reach a new equilibrium after the restrictive pressure is changed.
It is desnxable to not make more measurements than is necessary in order to reduce the test tune. A greater number of scans per measurement ovens out pulsatile variations. It has been found that nn.easurements yield different results, even taken at near the same time. Therefore, enough measurements should be made to ensure adequate results. Multiple cycles may be needed to produce satisfactory results. If the first few measurements give results with a smau standard deviation, it may not be necessary to Punish all the measurements.
'There are various tradeoffs in the choice of values. For example, a largC
change i~t blood volume is desiu-able to produce a High signal to noise ratio with respect to arterial pulsations. However, a large blood volmxte change takes a longer time azzd causes more capillary beds to open up to accommc~datu additional blood volume.
Of course, the various values and Limits for frequencies, steps, scans, repetitions, and cycles can be changed through altering the software.
7. A Neural Netwgrk Aa rp oach A neural network may analyze very complex noisy data and find patterns (or combinations of data) that can be used to determine underlying parameters.
These patterns are usually trot apparent to human observers. xn a statistical sense, neural networks are capable of performing noes-linear non-parametcic :egression.
Finding neural network solutions to complex data analysis problun~s may be as much art as science. There are many different neural network paradigms, and each of these paradigms use the specification of a number o#' critical parameters.
These choices require a certain amount of experieni;e, trial-and-error, etc.
The ~t r, ~AOEO SHEEN

i 7 L. d''J if ~ " - ~ . .-. . ~ .r .. ..

search for a systematic neural network design approach is a very active area of research within the field of Artificial Intelligence.
'X'he particular paradigms of interest in the present invention are believed to be those that produce continuous-valued outputs and that undergo supervised S training. 'I<'his is a technique of shaping the neural network in which the network is repeatedly exposed to both the data and the right answer. 'This allows the net to structure itself internally so that it extr~dcts the features in Lhe data that we have identi~f-ted as being important to the present invention.
Clinical ~.iata collectian could be gathered from severral runs on each patient or subject. The runs could be performed with certain varying c onditions (such as different height of the limb under test, applied heat to the limb, etc. j.
'Thereby, several different environments could be produced with different patterns of data for the same hetnatocrit. In addition, blood could be drawn to accurately determine the actual hematocrit using the '"gold standard" technique of centriLiying capillary tubes containing the subject's whale blood.
By collecting this diverse data an each subject and having a sufficient number of subjects, the neural nets will be trained to determine the underlying parameter of hematocrit.
Neural network S2 rnay be in PG 4:~ ou an adjacent 1;'C or other computer.
Accordingly, in FIG. 4, neural network 52 is shown In dashed lines.
The following parameters could be considered by the neural network. 'fVith respect to the impedance waveforrns, the neural network could consider parameters including frequency, magnitude, phase, and derivations thereof. '4~ith respect to the patient or subject, the neural network could consider parameters includiry the patient's age, weight, sex, temperature, illness, heat applied to the limb, blood pressure, and arm elevation and position. Of course, it is not necessary that the mural network consider each of these parameters.
Of course, the neural network would also consider the hematoc:rit measurements from centrifuLing capillary tubes corresponding to the patient from which the other factor's °.Vere obtained.
The neural network is used irb two manners. pirst, it is ~~s~.~d to derive a group of patterns and/or other data from a large amount of the l3ar°~uneiers regarding patients and waveforms. Second, once the patterns and/or other data are derived, ;~r,.,', v~.~~~~ll ~t-~r~~

S ~; U ~s 0'~! ~ 996 _z8_ the neural network is used i.n determining the hematocrit of a particular patient (who, for example, may be on an operating table) by comparing patient artd waveform data of the particular patient with the previously derived patterns andlor ,. other data.
At present, it is believed that the neural network is able to process out the small vessel effect and produce the hematocrit value due to blood contained in large vessels.
As used herein, the teem "patient" includes both those persons from whom the data is originally obtain to create the group of patterns or data, and those l0 persons whose hematocrit is cater deterTUirred from tire group of patterns or data.
Look up tables may be used, ~rlthough it is expected that many of the patterns (such as equations) rnay be too complicated to make look-ug tables practic~rl for most purposes.
8. Air purxtp, solenoid(sl, and_pressure cuff 28 IS There are various methods of changing the blood volume. For example, if limb 44 is a finger, blood volume may be changed through venous restriction about the upper arm of the patient, or arterial occlusion of the wrist of the patient.
In the case of venous restriction, it is preferred that the cuff create less than diastolic pressure so that arteries carr pump blood in, Bert blood does not flow out _ 20 under the cuff until pressure in limb 44. eduals the cuff pressure. Under arterial .
'~ occlusion, arterial blood is blocked from entering Limb 44 and hood drains out of limb 44 through the veins to create a lower blood volume. it has been found that the phase change detected dur7ng venous restricaion may be different from that detected during arterial occlusion.
25 It is believed to be easier to implement venous restriction with a blood pressure cuff than it is to perform arterial occlusion. To obtain restriction through occlusion, the ulna and radial arteries should be occluded, which rnay be difficult Also, about 10 ~ of the population has a medial ax'terial which shouIci also be occluded. However, it is believed that arterial occlusion drains the large vessels 30 without effecting thr: capillaries to a great extent while venous rrstric-tion has a greater tendency to open up new capillary bends andlor modify tine ~eornetry of the vascular space.

i i f~,l"~/ V 1','~ Lr V ~'1 V Y W J v.I V

Referring to FIG. 9, air pump, solenoid(s), and pressure cuff 28 may work as follows. An air pump 152 provides increased air pressure to a tube I54.
When it is time for a pressure cuff 15b to increase irt pressure, microprocessor 94 activates a solenoid 160 which allows the increased pressure in tube 154 to flow to tuba 162. Microprocessor 94 is informed of the pressure in tube 162 through pressure transducer 164. When it is time to decrease the pressure in cuff 156, microprocessor 94 activates solenoid 168 through which tube 1 b2 is connected to an exhaust. Air pump 152 may be turned on under separate switch or under the control of micro-processor 94.
The volume change should be maximized by adjusting the tilt and height of the patient's arm.
It is believed that limb movement may signifzeantly change the impedance.
9. Additional Information Frequency generator 1U0 may be constructed according tU a well known practice shown in F1G. 10. Referring to 1~'YG. 10, a lfi-bit frequency word FW
is received on conductor 11?. by an adder 180 that produces a phase word Pw in response to the FW. The desired sinusoidal freduency = FW X clock frequencyl 2~s. Depending on the maximum desired sinusoidal frequency, the clock frequency may be, for example, 30 MHz or 60 MHz. The phase word PW is received by a sinelcosine Look-up table PROM 182 that produces sine and cosine signals. The sine signal may be 127.5 x sin (PW x 2u)12048 and the cosine signal may be 127.5 cos (PW x 2-112048. Qf course, the preceding is merely an example and various other well known techniques could bi: used.
Preferably, current is injected into limb 44 brtwc°.~~n electrodes 4$A
and 4238, and voltage is measured b~aw~n elecarodes SUA and SOI3. Alte~r~atively and less desirably, current could be injected between electrodes SOA and 50I3, and voltage trteasured between electrodes 48A and 48I3. In the case of the alternative less desirable arrangement, preferably, bath the current injected by electrode 50A
and the current received by electrode SOB would be measurr:d to account for any current that may pass to another part of the body. Also, in the case of the alternative less desirable arrangement, it may also be desirable to bring electrodes SOB and closer to electrodes 48A and 50A, and to make the electrodes narrower.
Current could be created through magnetic fields rather than ek:etrodes.
At~i~ N9ED SHEEN

n°CH/U~ ~ ~ i~Ull I~~b Preferably, the out-o~ phase signals on conductors 98 from signal generator 100 are cosine signals, which are 90 degrees (or 270 degrees) out of phase with the sine signal on conductors 96 (sometimes called a quadrature signal).
Alternatively, the out-of-phase signals could have some other relationship than 90 degrees out of phase with respect to sine signals on conductors 96. In that case, it may be necessary and/or desirable to have three or more signals rather than only two signals.
In the illustrated embodiment of FIGS. 4 and 8, the functions of frequency generator 1U0, Iow pass filters I16 and 128, and mixer aced filters 1U4 and 1U6 are performed in hardware (including programmed dedicated hardware with, for example, adders, multipliers, and gate arrays) as opposed to a microprocessor.
Alternatively, some or all of the functions may be performed in PC.' 42, in another microprocessor system, or otherwise in software.
Of course, PC 42 does not have to be a "personal computer" but may be az~y of various other computers, such as a Macintosh, Sun Microsystems, etc.
Four mixers and filters may be used, rather than the two, elimlIlatmg the need for RF switch $U.
As used herein, a "conductor'' may actual comprise multiple wires, such as in the case of a parallel digital transmission. In another words, digital data may be transmitted in parallel or in series. There may also be a ground wire.
Conductors 3$ and 4U each may be a 50 ohm coaxial cable.
As used in the claims, the term "connect," "connectable," csr "connected to"
are not necessarily limited to a direct coruiection.
B. T~v o-Frecfu~ncX Embodimenss Although the multi-frequency embodiment described above is generally preferred, a description of the following two-frequency technique for determining the hematocrit is also presented.
1. Back round Refernng again to FIG. 1, wluich depicts an approxirn~ltic~n of thte behavior of whole blood when subjected to an alternating electrical current, resistance I0 in circuit path 12. repmsents the response of the extraceilular or plasma component, while the parallel circuit path 14> representative of the erythrocyte or red blood corpuscle component, includes both a capacitance I6 as well as a resistance I$. At ~:r,~r;~~nr~ SHF~r low frequencies (such as 50 kHz), whole blood impedance is attributable primarily to the extracellular blood component circuit path 12, while at higher frequencies (for example, 1 MHz) the capacitive nature of the cell membrane of the red blood corpuscles results in a more significant impedance contribution from circuit path 14, reducing the magnitude of the whole blood impedance. Thus, in simplified terms, the ratio of a low-frequency impedance to a high-frequency impedance is representative of the relative volume percent of red blood corpuscles, or hematocrit.
There is no precise frequency or narrow band at which the red cell capacitance phenomenon becomes significant, but rather a transition zone of frequencies over which the capacitive component increases in a relatively rapid manner. As will be explained in more detail hereafter, the impedance magnitude differential due to the frequency response characteristics of blood below and above the aforementioned transition zone enables the practitioner employing the present invention to utilize electrical stimulation of the patient to determine hematocrit in a noninvasive manner. However, in order to make use of frequency-based impedance differentials in whole blood to determine hematocrit, it is necessary to remove the dominant body tissue impedance component of the body portion through which impedance is measured.
FIG. 15 of the drawings comprises a representative sector of a demodulated voltage signal envelope over a period of time as measured by sensors attached to an electrically-stimulated extremity of a patient according to the present invention, the measured voltage being directly proportional to and therefore representative of the total impedance of the whole blood plus the surrounding tissue. As shown, the signal envelope includes a dominant DC or baseline component and a small AC or pulsatile component. The DC component is generated by the patient's tissue, non-pulsatile arterial blood, and venous and capillary blood of the stimulated body portion. The AC component is attributable only to the pulsatile blood, and is therefore truly representative of whole blood impedance for a given frequency.
AC
components at different frequencies will have substantially identical voltage envelope shapes, differing only in magnitude due to the aforementioned frequency-dependent nature of the whole blood impedance response. By isolating and utilizing only the AC, or pulsatile, component of the signal, the impedance effects of the patient's extravascular tissue are eliminated and a hematocrit determination may be made using the ratio of a low-frequency pulsatile impedance to a high-frequency pulsatile impedance.
2. Two-frequency system and method FIG. 11, which is illustrative of a two-frequency embodiment of the invention, shows a patient body portion 220 containing an artery (which may also be referred to as a pulsatile vascular compartment) on the exterior of which have been placed outer stimulation electrodes 222 and inner sensor electrodes 224, all of which are preferably ring electrodes so as to envelop the body portion 220.
The four-electrode method is a standard engineering technique which helps to eliminate errors attributable to contact resistance and, except insofar as it is employed in the present invention, does not constitute a part thereof.
Power or stimulation electrodes 222 are driven with a constant current composite carrier waveform consisting of two frequencies A and B provided by current sources 226 and 228. It is preferred that the applied constant current be of a peak-to-peak magnitude of 2 mA or less. Frequencies A and B should differ sufficiently to provide a significantly different blood impedance response to each frequency due to the capacitive component of the patient's blood, and thus an impedance differential useful in practicing the present invention. It has been found that a low frequency A of 50 kHz and a high frequency B of 1 MHz provide a usable differential response, in that they are, respectively, sufficiently far below and above the frequency transition zone wherein the capacitive component of the response becomes significant. It should be noted at this point that use of frequencies much below 50 kHz is inadvisable for reasons of patient safety, in that lower frequencies may induce heart arrhythmia.
Each frequency excites the tissue of body portion 220 with a constant current, and the resulting voltage signal at each frequency is measured from inner sensor electrodes 224. Since the current excitation is constant, the envelope of the measured voltage at each frequency is directly proportional to the tissue impedance at that frequency. AM Detectors 230 and 232, one each for frequency A and frequency B, measure the envelope of the voltage signals, and transmit the resulting signals to A/D Converter 234, which converts the signals to the digital domain for isolation of the pulsatile component of the signal and further processing by a programmed processing unit, preferably general purpose Microcomputer 236, in .-response to commands from Keyboard 238. Microcomputer 236 repeatedly extracts time-matched converted pulsatile signal component segments at each frequency, normalizes them against the voltage baseline of the respective carrier waveforms and then creates a series of segment ratios of the normalized pulsatile signal components. These ratios are averaged, preferably using a weighted averaging methodology which more heavily weights more significant ratios, being those comprised of pulsatile component segments exhibiting the greatest change in voltage magnitude over time. The weighted average of the ratios is representative of the hematocrit, the latter being extracted from an internal look up table of corresponding ratio and hematocrit values by Microcomputer 236, and displayed to the practitioner via Display 240, which may comprise a graphic screen display, a numerical display, or both. ' An embodiment of current sources 226 and 228 of FIG. 11, as depicted in FIG. 12, uses transistor 300 as an approximation of a current source, which is driven by oscillator 302 through automatic gain control (AGC) multiplier 322 at the desired frequency, the resulting output signal driving power transformer 304 which in turn outputs to patient stimulation electrodes 222. Isolation of each current source using transformer coupling via power transformer 304 and pickoff transformer 306 is used for patient safety. It should be noted that, as is well known in the art, transformers 304 and 306 should be wound to maximize their response at the frequencies of interest and minimize sensitivity to artifact. A sensing or regulator signal is picked off from the output coil of transformer 306 and transmitted through buffer 308 to phase lock loop synchronous AM detector 317, which includes detector multiplier 310, phase lock loop 312, quadrature amplifier 314 and low pass filter 316. Phase lock loops are well known in the art, as are AM
synchronous detectors incorporating same, and therefore their structure and function will not be further described herein. However, a brief but excellent description of phase lock loops, their operation, versatility and applications, specifically in the fabrication of an AM synchronous detector suitable for use with the present invention, appears in the 1987 EXAR Databook, pp. 6-62 through 65 and 11-68 through 71, published by F.XAR Corporation, 2222 Qume Drive, San Jose, California 95131. Detector 317 outputs the envelope of the sensed current drive signal to difference amplifier 318 for comparison to the input signal from reference irr~vu5 ~- ~ ~~~ v ~~~~

320, the output signal from; difference amplifier 318 controlling AGC
multiplier 322, the output of which is impressed with the desired frequency (A or B) by oscillator 302. Thus a servo-control loop to maintain a substantially constant output from the current source is established. Current Sources 226 and 228 are S substantially identical except for the frequencies dictated by oscillator 302.
The Al~ Detectors 230 and 232 used in the embodiment of FTG. 11 of tlue present invention, as depicted in ~'IG. 13, are AM synchrony>us detec.tc~rs built around a phase lock loop. 1'he measured voltage signal from the sensor or patient measurement electrodes 224, which is quite minute, is ampLihed by instrumentation amplifier 400 and sent to detector multiplier 402 and phase Lock loop 404 of each AM Detector 230 arid 232, the output of the phase lock loops being filtered by low pass filters 408. The outputs of Detectors 230 and 232 are thus the envelopes of the measured voltage waveforms at low and high frequencies, respectively, and inherently representlative of impedan<:e at those frequencies. As noted previously, phase loch loops and synchronous A1W detectors, their structure and function are well lmown in the art, and the reader is again referred to the above-referenced pages of the 19$7 F.XAIRDatabook for a more detailed description thereof.
The demodulated voltage sigrr~l envelopes from AM 1)et<:ctors 23() and 232 are received by AID ('onverter 234, depicted in its preferred embodiment in FIG.
14, AID Converter 234 including a pair of level shifters 5()0, each driven by level set commands from lVicrocomputer 236 via digittal~to-analog (D/A) convertors to extend the range of high resolution analog-to-digital (A!D) converter unit 504 to accommodate the fact that the variable {pulsatile) component of the impedance being measured typically constitutes only about one percent (1 %) of the total measured impedance. Analog ntultiplexor 506 selects the appropuiate signals from either ,Al~T
Detector 230 or 232 responsive to channel select commands from lvlicrocomputer 236, and feeds the selected signal to analog-to-digital converter unit 504 for conversion to the digital domain.
One preferred means of obtaining the pulsatile wave:orm component of interest in the practice of the present invention i.s to utilize a hii;h resolution AlD
converter unit :i04; that is to say one which has a ~()-f_ > bit resoiutic~n capability.
and digitise the entire waveforYn, ineludic~g both tfae small Ai:: (puisatile) and much larger DC (baseline) components. 'this provides a sufticient'~r Large dynamic range -... ~ YV A v v Y v m v w so that the pulsatile, or AC component, of the waveform at each frequency can be isolated to provide meaningful data. ~iowever, this approach requires a relatively expensive A,lD converter unit, and an alternative approach is to set a voltage clamp level at the magnitude of the DC component, subtract this from the waveform and magnify the remaining signal. The voltage clamp approach is less expensive as it requires fewer bits of resolution capability in the AID convener unit.
Segments of the converted anaog values from Detectors Z30 and 232 are then repeatedly extracted over identical time periods by Microcomputer 236, correlated to further reduce noise effects, and then narnnalized by dividing by the voltage baseline of their respective carrier waveforms before a series of ratios of the time-matched digitized pulsatile component signal segments at frequencies A
and B
are calculated. The ratios are averaged in a preferred embodiment using weighted averaging techniques well known in the art, relative weighting being based upon the change in voltage magnitude versus time for the time period over which the digitizxd signals ane extracted. Stated another way, the greater thG ~V per nt for a pair of time-matched component segments, the more significant the resulting ratio and the more heavily the ratio is weighted in the averaging process. The weighted ratio average, which is representative of hematocrit, is correlated to a hematocrit value by Microcomputer 236 via a look-up table of corresponding ratio and hematocr~it values constructed a priori from clirrical studies acrd depicted numerically andlor graphically to the practitioner on Display 240. Of course, the foregoing process from measurement of voltage across the patient body portion 220 to ultimate output of patient hematocrit on Display 240 is performed repeatedly and substantially continuously, so that variations and trends in hematocrit will be immediately apparent. 'I'tre use of empirical data for the loon-up table is due to the fact that the electrical approximation employed for the wholr, blood tnc~del is frrst-order, acrd a rigorous derivation of the response of the model will be inaccurate.
Moreover, any such derivations will yield calibration results which vary with the two frequencies chosen, as well as the gain factors of the vazious stages of the 3Q apparatus.
As will be evident to the. skilled pzactitioner of the art, all components of the apparatus utilized to practice tire present invention should be selo<aed for low noise o;rtput, due to the extremely low signal rnagnituda of the signal of interest.

~ ~v'r l ivWJ
-2fi-3. Arid ~,~~ (",.~m~,_",arid a. ')=he Impedance of Blood The model. for the first-order electrical representation of blood, as shown in FIG. 1, has been established by empirical testing to be correct. It is interesting to note that confirmation of the model has appeared in the biomedical engineering literature. de Vries, P.M.J.M., et al. "Implications of the dielectrical behavior of human blood for continuous on-line measurement of hematocrit", Med, Biol.En~.
& Comput. 31, 4~15~448 (1993).
However, the frequency range of greatest interest, previously believed to lie between 50 kHz and x MHz, has been proven to be somewhat different and expanded at the hzgh frequency end. In fact, the preferred frequency range has subsequently been established to lie substantially between 100 kHz amd i0 MHz to MHz.
The electrical performance characteristics of blood according to the FIG. 1 15 model over this latter frequency ranl;e (100kHz an<i 10 MHz to 20 ?VIHz) have been confirmed by the inventor on numerous occasions with a specially prepared test cell.
The test cell was fabricated by taking a cylindrical glass tube 1 cm in diameter.
One end was sealed with an insulator containitr,g an embedded electmde. The blood sample was then introduced into the test cell, together with a very small quantity of 20 heparin, to prevent the sample from coagulating in the test cell. ,A
removable stopper of an insulating material was then imserted in the open end of the test cell;
the stopper also had an embedded electrode that descended into the bioad, when the stopper was properly positioned. The impedance characteristic of the blood was then measured in a straight-forward manner (in this configurati<~r~, the test cell operates as a two~terminal electrical device) by douy a frequency sweep over the range of interest and measuring the response.
Since stagnant blood has a sf:dirnentation eft~o~a, in which the suspended red blood cells will slowly settle due to gravity, it may be important to stir the contents of the test cell if protractei-1 testing is done, to ensure reproducibility.
b. 'fhe Elecarieal Model for Noninvasive ~Iematac:rit Detern~ination By way of providing those of ordinary skill in the art with a more complete and comprehensive understanding of the invention, it sbould be reaffirmed that the ... __..,-.,~~ cmr~T

underlying electrical model is a parallel one. In fact, although the analogy employed in the BACKGROUND section of this application to pulse oximetry might be appropriate for motivation with what is now termed the "small signal" or plethysmographic approach, the analogy would be somewhat inappropriate if carried to an extreme. Specifically, a directly equivalent electrical derivation to the optical problem of pulse oximetry would result in a series electrical model. However.
the appropriate electrical model for a body portion 220 under test, as shown in FIG.
11, would be the first order approximation of FIG. 1 representative of the blood in the pulsatile vascular compartment, in parallel with a like circuit, the values of which would represent the infra- and extra-cellular spaces and cell membrane capacitances of the bulk background tissue. This model is shown in FIG. 16, where the background tissue impedance, ZT, is bridged in a parallel fashion by the impedance of an additional volume of blood, ZB. One naturally occurring way in which an additional volume of blood is added to a limb segment is during the cardiac cycle, where the pumping action of the heart causes incremental volumes of blood to be periodically added and removed. As shown in FIG. 16, ZB = Blood Impedance RBE = Extracellular Resistance of Blood RBI = Intracellular Resistance of Blood CBM = Cell Membrane Capacitance ZT = Tissue Impedance R~ = Factracellular Resistance of Tissue Rz.I = Intracellular Resistance of Tissue Cz.I,,i = Cell Membrane Capacitance of Tissue The solution of this model is straightforward, and can be done by any electrical engineer of ordinary skill in the art. Successful solution techniques find ZB by removing the effect of ZI. from the measured gross impedance, using knowledge of the parallel nature of the model. Once ZB is determined, hematocrit is found to be some function of the ratio RBI/(RBI + RB~. The precise characterization of this function cannot be known; however, it is empirically determined during instrument design by making a large number of calibration-type measurements and embedding the results in a look-up table as previously referenced. The look-up table is then employed in the apparatus of the invention as used with a patient in a real-life environment.
Using the underlying concept of measurement at sufficiently low frequencies that the capacitances are essentially apen circuits (less than 100 kHz ( < 100 kHz)), and at sufficiently high frequencies that the capacitances are essentially short or closed circuits (greater than 20 MHz ( > 20 MHz)), results in simplified equations for solution of the problem.
c. The Two-Freduency Technickue The original inventive concept, as set forth above, addresses the problem (hematocrit determination) from the point of view of impedance magnitude.
Since the equivalent electrical circuits used to model the pertinent physiology contain reactive components (capacitors), the impedance across the frequency spechum is complex; i.e., magnitude and phase are both pertinent (or, equivalently, real and imaginary pmts).
However, as noted immediately above, by using measurement frequencies that are sufficiently low and sufficiently high, the capacitive components are either respectively open or closed. Thus, the phase at the measurement frequencies would be expected to be at or near zero.
Practically speaking, it is difficult to fabricate electrical devices that perform well at 20 MHz, in order to solve the noninvasive hematocrit determination problem.
It is possible, however, to use a two frequency technique where the higher of the two frequencies is lower than 20 MHz if additional assumptions are made. For example, the reverse S-shaped curve plot of blood impedance, Z, which is level at 100 kHz and then slopes downwardly above 100 kHZ until it is again level at 20 MHz, begins to level out at about 10 MHz. Therefore, one may achieve reasonable accuracy by employing a look-up table with high frequency empirical values corresponding to hematocrit as determined at 10 MHz rather than 20 MHz. Alternatively, it is possible to solve the equations represented by the circuits by using more than two frequencies, for example, three or more, if these are chosen so that the measured impedances at these frequencies are sufficiently different from one another. The use of at least one additional frequency would again permit the avoidance of using a 20 MHz high frequency. This technique would involve more mathematics with at least another additional unknown, but potentially is a more refined methodology which might obtain a better approximation of hematocrit at certain levels via curve-fitting than the two-frequency approach.
~-WO 96!32883 PCT/US96/04547 The approach of the system and method of FIGS. 3-10, however, does not ignore phase. It has been determined that phase angle (phase shift) of a detected waveform relative to the input signal is related to the amount of cell membrane present, and thus to hematocrit. Further, if blood is directly measured in a test cell, as previously described, but both magnitude and phase are recovered, the inventor has found that the phase reaches a maximum response in the vicinity of 1.6 MHz (also confirmed by de Vries, et al, previously cited). This is the frequency region approximately corresponding to the point of inflection of the reverse S-shaped impedance/frequency curve. Thus, if appropriate hardware is fabricated, the noninvasive hematocrit determination problem can be solved with a two frequency measurement employing the phase of the detected signals in combination with impedance magnitude, wherein the high frequency is significantly lower than 20 d. The Modified Small Si n~pproach As discussed earlier with respect to the two-frequency embodiment of the invention, when a limb containing a pulsatile vascular space is measured electrically, the pulsatile component (!mown as the plethysmographic signal) is a very small percentage of the baseline DC signal. Typically, this plethysmographic signal is 0.05 % - 0.1 % of the magnitude of the baseline. This in itself requires very rigorously designed instrumentation, as heretofore noted, because of the necessary dynamic range.
However, an additional problem has been discovered with the small signal approach as described with respect to the two-frequency embodiment of the invention. This problem is due to the nature of intracorporeal blood-flow, which the inventor has determined to be non-homogeneous. By this, it is meant that the gross components of blood, namely plasma and the suspended cellular particles, do not flow in lock-step with one another; rather, in response to irregular paths, turbulence, etc., the concentration of red cells in plasma may exhibit regions of higher concentration followed by regions of lower concentration. Thus, over the course of a cardiac cycle, there will be small changes in the "instantaneous hematocrit" at any given point in a vascular space. Thus, if one could station a miniature "perfect observer" at a given point in an artery, this observer might detect instantaneous hematocrits varying from 39 to 41 in a person whose classically measured hematocrit was 40.
While seemingly small in absolute terms, such variations in instantaneous hematocrit tend to have a rather large effect on the derived hematocrit, when the noninvasive technique of the invention is used. This phenomenon results from the underlying assumption that the plethysmographic variations that are observed are due strictly to variations in the observed volume of whole blood, and are representative of whole blood. In fact, the measured variations are a combination of true blood volume change as well as changes in the local density of red cells in plasma. It is conceivable that the relative percentage of the density variation is actually larger than the plethysmographic percentage of the baseline. This situation may lead to markedly incorrect results, even if an ideal apparatus were to be built.
A solution to the aforementioned problem with using the small signal approach created by variations in instantaneous hematocrit, is to restore correctness to the underlying assumption of homogeneity of blood flow. This modified small signal approach is effected by applying a mechanical "assist" to the limb under measurement. To understand the basis for this "assist," consider what happens when a blood pressure cuff is applied to a limb and taken through an inflation-deflation cycle. When the cuff is initially taken up to a pressure that exceeds systolic blood pressure by a fair amount, the pressure results in the complete obliteration of the arterial space; consequently, no blood will flow past the obstruction effected by the cuff at any point in the cardiac cycle and the plethysmographic signal is completely suppressed. As the cuff bleed valve is opened and the cuff is deflated slowly, the column of blood at the proximal end of the cuff is able to make brief incursions into the region of the limb under the cuff during the high pressure parts of the cardiac cycle. Just as the cuff deflates to sys-tolic pressure, a small quantity of blood is able to completely traverse the occluded zone for just a brief instant. As the cuff pressure continues to decrease, a larger fraction of blood is able to transit through the occlusion zone, although there is still complete occlusion of the artery for the portion of the cardiac cycle that has a pressure below the occluding cuff pressure. Finally, as the cuff deflates to diastolic blood pressure, the blood is able to travel past the occlusion zone for the entire cardiac cycle.

R'O 96/32883 PCT/US96/04547 Now, consider again the situation where the cuff pressure is just at the systolic value. The tiny fraction of blood that is able to completely traverse the occlusion zone is nearly pure plasma, because plasma is less viscous than whole blood and the resistance of the nearly totally occluded artery is very high. As the cuff pressure continues to decrease, the resistance presented to the blood also decreases, and more cellular components are able to flow. The desirable effect being sought is one where the artery remains occluded for at least a small portion of the cardiac cycle and where the blood traversing the occlusion zone is representative of whole blood, at least over time.
Thus, by causing the artery to be occluded by a blood pressure cuff during a portion of the cardiac cycle, it is guaranteed that the plethysmographic signal is representative of the total volume of blood in the artery, rather than the small portion of additional volume due to cardiac ejection. Additionally, if the blood traversing the occlusion zone is representative of whole blood over time, then the plethysmographic waveform can be integrated to solve the problem.
It has been found that the proper conditions to effect the foregoing desired result occur when the cuff pressure is in the region of mean arterial pressure. This pressure zone is non-critical and corresponds to the pressure region where the amplitude of the plethysmographic component of the signal becomes a maximum.
To practice the invention according to this methodology, the cuff is applied to the body portion (limb) in question proximate the stimulation and sensor electrodes.
It is feasible to place the cuff either proximally, distally or over the electrodes, there at present being no identified preferred location for the cuff relative to the electrodes. Pressure in the cuff and inflation and deflation thereof may be controlled via a pump, bleed valve and sensor (pressure transducer) as known in the art, which devices are preferably under control of the microcomputer of the hematocrit determination apparatus.
It should also be observed that the modified small signal approach should be employed with simultaneous stimulation of the body portion in question at the two selected frequencies, due to the importance of fairly precise synchronization of sampling with the timing of the cuff inflation/deflation cycle.

e. The Large Signal Approach The multi-frequency approach described in connection with FIGS. 3-10 is referred to as a large signal approach. By contrast, the two-frequency approach is .
referred to as a small signal approach. An underlying impedance effect has been discovered and verified that allows the determination of hematocrit using electrical -measurements. The concept is extended to the noninvasive realm by observing blood plus background tissue and focusing in on the component that is due to blood;
i.e., subtracting out the portion of the effect that is due to the background tissue.
Naturally occurring variations in blood volume due to the actions inherent in the cardiac cycle are used by measuring the plethysmographic signals. In the previously-discussed small signal approach, a blood pressure cuff is employed to avoid the deleterious effects of the non-homogeneous nature of blood flow.
A large shift in blood is effected by the system and method described in connection with FIGS. 3-10. The nature of the method is such that blood flow artifact is eliminated. The same concept of subtracting out the background tissue impedance is employed, using the equations that result from solving the parallel model.
The procedure requires that an initial measurement of the background be taken with the limb under examination at rest, a blood pressure cuff having been previously applied. The cuff is then inflated to a point that is just below diastolic blood pressure. This pressure level allows blood flow during the complete cardiac cycle through the arteries; however, the cuff pressure is sufficient to provide venous occlusion. For purposes of convenience, a vein may also be referred to as a non-pulsatile vascular compartment. Thus, a situation has been created where whole blood is being added to the limb while outflow of blood is prevented. This serves to temporarily sequester an additional volume of whole blood in the vascular space of the limb. If, now, an additional measurement is taken, it becomes a simple matter using the aforementioned background measurement in combination with the additional measurement to apply the equations that solve the parallel model (FIG.
16) to derive the hematocrit. It has been determined that the differential signal magnitude that results as a consequence of this maneuver is on the order of 2 % -5 % , which is a significant improvement over the magnitude of the plethysmographic signal in comparison to the baseline. It should also be noted that the large signal o-approach is a static technique in which the sequestered increment of blood is not flowing during the period of measurement. As a result, the artifact due to non-homogeneous blood flow is eliminated. Further, because the large signal approach is a static technique, stimulation of the patient body portion at different frequencies may be effected sequentially rather than simultaneously, via sweeping or rapidly sampling at the desired frequencies.
The operation of the blood pressure cuff to effectuate the large signal approach, is preferably controlled, as with the small signal approach, by the microcomputer of the hematocrit determination apparatus.
C. Measurement of Blood Pressure Since the measurement setup for both the modified small signal and the large signal approach involves the application of a blood pressure cuff, as well as the electrodes necessary for impedance measurement, the apparatus may also be used to provide for the measurement of blood pressure using a different technique than that which is commonly employed in present day noninvasive automatic blood pressure monitors.
Current technology for automatic blood pressure monitoring generally employs the oscillometric approach. This involves analysis of the pressure variation in the blood pressure cuff itself that is due to pulsation in the arteries that underlay the cuff. Such an approach has been recognized to result in reasonably accurate values for systolic and mean blood pressures, but usually inaccurate values for diastolic blood pressure. However, the oscillometric technique has found widespread acceptance due to the simplicity, from the user's point-of view, of employing the cuff as both the medium of pressure application as well as the sensing device.
This results in a favorably perceived trade-off between inaccuracy of measurement of diastolic pressure versus ease-of use.
Although the blood pressure determination technique of the invention involves the connection of additional interfaces to the patient, this is already being done to obtain the hematocrit noninvasively. Therefore, it is attractive to use the apparatus of the invention to also obtain a blood pressure reading that is, in fact, more accurate than that afforded by the oscillometric technique.

WU 96/32883 PCTlUS96/04547 The measurement points of interest using a blood pressure cuff and impedance determination electrodes and circuitry are found as follows: the cuff is inflated initially to suppress the plethysmographic signal; as the cuff is deflated, systolic , pressure is the point at which the plethysmographic waveform reappears; as cuff deflation continues, mean arterial pressure is the point of maximum intensity of the plethysmographic signal; as cuff deflation continues still further, diastolic pressure is that at which the morphology of the plethysmographic waveform ceases to undergo further change with continued cuff deflation.
D. Conclusion While the present invention has been described in terms of certain exemplary preferred embodiments, it will be readily understood and appreciated by one of ordinary skill in the art that it is not so limited, and that many additions, deletions and modifications to the preferred embodiments may be made within the scope of the invention as hereinafter claimed.
~-

Claims (81)

What is claimed is:
1. A system for noninvasive determination of hematocrit of blood in a body portion of a patient, the system comprising:
signal generation circuitry to produce alternating and quadrature signals at various frequencies;
processing, sensing, and application circuitry to provide current signals through the body portion in response to the alternating signals, and to sense the current signals being applied and produce current indicating signals in response thereto, and to sense voltage signals over a section of the body portion and produce voltage indicating signals in response thereto;
processing and demodulation circuitry to receive and mix the current indicating signals and the alternating and quadrature signals to produce inphase and quadrature current representing signals, and to receive the voltage indicating signals and mix the voltage indicating signals and the alternating and quadrature signals to produce inphase and quadrature voltage representing signals; and evaluation circuitry to receive and process the inphase and quadrature current representing signals and inphase and quadrature voltage representing signals to determine the hematocrit.
2. The system of claim 1 in which the evaluation circuitry includes a neural network in which parameters of the processed inphase and quadrature current representing signals and inphase and quadrature voltage representing signals are included in a comparison with pre-gathered data to determine the hematocrit.
3. The system of claim 2 in which parameters regarding the patient axe also included in the comparison.
4. The system of claim 2 in which the pre-gathered data includes parameters regarding processed inphase and quadrature current representing signals and inphase and quadrature voltage representing signals of various persons other than the patient.
5. The system of claim 1 in which the evaluation circuitry has access to and considers a group of hematocrit data representative of numerous persons.
6. The system of claim 1 further comprising a blood flow restriction device for restricting flow of blood in the body portion, thereby allowing blood volume in the body portion to change between at least a first and a second volume;
and in which the processing, sensing, and application circuitry produces current indicating signals and voltage indicating signals for at least the first and second volumes.
7. The system of claim 6 in which the blood flow restriction device includes a pressure cuff.
8. The system of claim 1 in which the body portion includes a portion of a finger of the patient.
9. The system of claim 1 in which the various frequencies range from kHz to 10 MHz.
10. The system of claim 1 in which the processing and demodulation circuitry is included in a microprocessor system.
11. The system of claim 1 in which the signal generation circuitry is included in a microprocessor system.
12. The system of claim 1 in which the processing and demodulation circuitry and the signal generation circuitry are included in a microprocessor system.
13. The system of claim 1 in which the processing, sensing, and application circuitry includes a switch through which the voltage indicating signals and current indicating signals alternatively pass.
14. The system of claim 1 in which the processing and demodulation circuitry includes low pass filters with outputs and the inphase and quadrature current representing signals, and inphase and quadrature voltage representing signals are provided at the outputs of the low pass filters.
15. A system for noninvasive determination of hematocrit of blood of a patient, the system comprising:
signal generation circuitry to produce alternating signals at various frequencies and out-of-phase signals with respect to the alternating signals;
processing, sensing, and application circuitry to provide current signals through the blood in response to the alternating signals, and that senses the current signals being applied and produces current indicating signals in response thereto, and that senses voltage signals over a section of the blood anal produces voltage indicating signals in response thereto;
processing and demodulation circuitry to receive and mix the current indicating signals and the alternating and out-of-phase signals to produce inphase and out-of-phase current representing signals and to receive the voltage indicating signals and mix the voltage indicating signals and the inphase and out-of-phase voltage representing signals to produce inphase and out-of-phase voltage representing signals; and evaluation circuitry to receive and process the inphase and our-of-phase current representing signals and inphase and out-of-phase voltage representing signals to determine the hematocrit.
16. The system of claim 15 in which the evaluation circuitry includes a neural network in which parameters of the processed inphase and out-of-phase current representing signals and inphase and out-of-phase voltage representing signals axe included ire a comparison with pre-gathered data to determine the hematocrit.
17. The system of claim 16 in which parameters regarding the patient are also included in the comparison.
18. The system of claim 16 in which the pre-gathered data includes parameters regarding processed inphase and out-of phase current representing signals and inphase and out-of phase voltage representing signals of other persons.
19. The system of claim 15 in which the section of blood is in a limb of the patient, and further comprising a blood flow restriction device for restricting flow of blood in the limb, thereby allowing blood volume in the limb to change between at least a first and a second volume; and in which the processing, sensing, and application circuitry produces current indicating signals and voltage indicating signals for al least the first and second volumes.
24. The system of claim 15 in which the processing, sensing, and application circuitry includes two outer electrodes and two inner electrodes applied to a limb of the patient, and the current signals are applied through the two outer electrodes and the voltage signals axe sensed through the two inner electrodes.
21. The system of claim 15 in which the processing, sensing, and application circuitry includes two outer electrodes and two inner electrodes applied to a limb of the patient, and the current signals are applied through the two inner electrodes and the voltage signals axe sensed through the two outer electrodes.
22. The system of claims 15 in which the out-of-phase signals are quadrature signals with respect to the alternating signals.
23. A system for noninvasive determination of hematocrit of whole blood in a body portion of a patient, the system comprising:
signal generation means for producing alternating and quadrature signals at various frequencies;
processing, sensing, and application means for providing first signals through the body portion in response to the alternating signals, and sensing the first signals being applied and producing first indicating signals in response thereto, and sensing second signals over a section of the body portion and producing second indicating signals in response thereto;
processing and demodulation means for receiving and mixing the first indicating signals and the alternating and quadrature signals to produce inphase and quadrature first representing signals, and receiving the second indicating signals and mixing the second indicating signals and the alternating and quadrature signals to produce inphase and quadrature second representing signals; and evaluation means for receiving and processing the inphase and quadrature first representing signals and inphase and quadrature second representing signals to determine the hematocrit.
24. The system of claim 23 in which the evaluation means includes a neural network in which parameters of the processed inphase and quadrature first representing signals and inphase and quadrature second representing signals are included in a comparison with pre-gathered data to determine the hematocrit.
25. The system of claim 24 in which parameters regarding the patient are also included in the comparison.
26. The system of claim 24 in which the pre-gathered data includes parameters regarding processed inphase and quadrature first representing signals and inphase and quadrature second representing signals of other persons.
27. The system of claim 23 further comprising a blood flow restriction means for restricting flow of blood in the body portion, thereby allowing blood volume in the body portion to change between at least a first and a second volume;
and in which the processing, sensing, and application means produces current indicating signals and voltage indicating signals for at least the first and second volumes.
28. A method for noninvasive determination of hematocrit of blood in a body portion of a patient, the method comprising:

injecting alternating current signals having various frequencies into the body portion at different blood volumes, the injected alternating current signals being responsive to generated alternating signals having the various frequencies;
providing current indicating signals representative of the current signals injected into the body portion;
measuring voltage signals across a section of the body portion through which the current signals pass;
providing voltage indicating signals representative of the measured voltage signals;
mixing the current indicating signals with the generated alternating signals and with quadrature signals to produce inphase and quadrature current representative signals;
mixing the voltage indicating signals with the generated alternating signals and with the quadrature signals to produce inphase and quadrature voltage representative signals; and determining the hematocrit by considering parameters of the inphase and quadrature current representative signals and the inphase and quadrature voltage representative signals.
29. The method of claim 28 in which the step of determining the hematocrit includes employing a neural network in which parameters of the processed inphase and quadrature current representing signals and inphase and quadrature voltage representing signals are included in a comparison with pre gathered data to determine the hematocrit.
30. A system for developing a group of data with which a hematocrit of blood of a particular patient may be determined, the system comprising:
signal generation circuitry that produces alternating and quadrature signals at various frequencies;
processing, sensing, and application circuitry that provides current signals through a body portion of numerous patients in response to the alternating signals, and that senses the current signals being applied and produces current indicating signals in response thereto, and that senses voltage signals over a section of the body portion produces voltage indicating signals in response thereto;
processing and demodulation circuitry that receives and mixes the current indicating signals and the alternating and quadrature signals to produce inphase and quadrature current representing signals, and receives and mixes the voltage indicating signals and the alternating and quadrature signals to produce inphase and quadrature voltage representing signals; and evaluation circuitry that receives and processes the inphase and quadrature current representing signals and inphase and quadrature voltage representing signals and compares parameters of the inphase and quadrature current representing signals and inphase arad quadrature voltage representing signals with various pre-gathered data to produce the ,group of data.
31. An apparatus for noninvasive determination of the relative volume percent of erythrocytes, also termed the hematocrit, of blood having an impedance, comprising:
means for producing a constant current at a first low and at least one second high carrier wave frequencies, said first low frequency being below a frequency zone within which said erythrocytes significantly affect the magnitude of the impedance of said blood, and said at least one second high frequency being within said frequency zone;
means for stimulating a patient body portion including at least one pulsatile vascular compartment containing said blood with said first low and said at least one second high frequency current;
means for sensing voltage signals at each of said first low and said at least one second high carrier wave frequencies across said stimulated patient body portion;
means for amplifying said sensed voltage signals;
means for demodulating said amplified, sensed voltage signals to produce at least two complex waveforms respectively proportional to the magnitude of impedance of said blood at sand first low and said at least one second high carrier wave frequencies; and means for processing said at least two complex waveforms to determine said hematocrit of said blood.
32. The apparatus of claim 31, wherein said means for producing a constant current at said.first low and said at least one second high carrier wave frequencies comprises a signal generator in combination with a constant current amplifier, and said means for processing determines said first low and said at least one second high carrier wave frequencies.
33. The apparatus of claim 32, wherein said signal generator includes a first and a second adder paired respectively with a first and a second sine/cosine look-up table, to produce each of said fast low and said at least one second high carrier wave frequencies.
34. The apparatus of claim 33, wherein said first and second look-up tables each produce a sine output, and said signal generator further includes a third adder for summing said outputs and an analog-to-digital converter for converting said summed sine outputs to the digital domain for receipt 6y said constant current amplifier.
35. The apparatus of claim 32, wherein said signal generator generates a voltage waveform for conversion by said constant current amplifier to a constant current source.
36. The apparatus of claim 31, wherein said means for amplifying comprises a voltage detector.
37, The apparatus of claim 36, wherein said voltage detector comprises an instrumentation amplifier with common made rejection.
38. The apparatus of claim 31, wherein said means for demodulating comprises a signal generator and a signal demodulator.
39. The apparatus of claim 38, wherein said signal generator includes a first and a second adder paired, respectively, with a first and a second sine/cosine look-up table, to produce each of said first low and said at least one second high carrier wave frequencies.
40. The apparatus of claim 38, wherein said signal demodulator includes a paired low pass filter and an analog-to-digital converter for receiving said amplified voltage signals.
41. The apparatus of claim 40, wherein said signal demodulator further includes a first, second, third and fourth mixer paired, respectively, with a first, second, third and fourth digital low-pass filter, each of said mixer/filter pairs receiving the output of said paired low-pass filter and analog-to-digital converter and one of a first sine output or a first cosine output from said first look-up table or a second sine output ox a second cosine output from said second look-up table, said paired mixers and digital low-pass filters outputting said at least two complex waveforms.
42. The apparatus of claim 31, wherein said first low carrier wave frequency lies at about 100 kHz, and said at least one second high carrier wave frequency lies within the range from about 10 MHz to about 20 MHz.
43. The apparatus of claim 31, further comprising means for selectively occluding said pulsatile vascular compartment.
44. The apparatus of claim 43, wherein said selective occlusion comprises partial occlusion.
45. The apparatus of claim 44, wherein said selective exclusion comprises substantially total occlusion.
46. The apparatus of claim 43, wherein said means for selectively occluding comprises an inflatable cuff surrounding said patient body portion.
47. The apparatus of claim 46, wherein said selective occlusion is performed by pressurizing said cuff in the region of the mean pressure of said pulsatile vascular compartment.
48. The apparatus of claim 43, wherein said means far selectively occluding is located on said patient body portion proximate said means for stimulating and said means for sensing.
49. The apparatus of claim 43, wherein said means for selectively occluding is controlled by said means for processing.
50. The apparatus of claim 31, wherein said patient body portion further includes at least one non-pulsatile vascular compartment, and said apparatus further includes means for selectively occluding said at least one non-pulsatile vascular compartment while said at least one pulsatile vascular compartment remains unoccluded.
51. The apparatus of claim 50, wherein said means for selectively occluding comprises an inflatable cuff surrounding said patient body portion.
52. The apparatus of claim 50, wherein said means for selectively occluding is controlled by said means for processing.
53. The apparatus of claim 31, further comprising means for compensating for non-homogeneous flow of said blood through said pulsatile vascular compartment in determining said hematocrit of said blood.
54. The apparatus of claim 31, further comprising means for determining blood pressure of said blood in said pulsatile vascular compartment.
55. The apparatus of claim 54, wherein said means for determining said blood pressure includes means for selectively occluding said pulsatile vascular compartment.
56. The apparatus of claim 55, wherein said means for selectively occluding said pulsatile vascular compartment is controlled by said means for processing to completely occlude said vascular compartment, and to subsequently reduce said complete occlusion by a degree sufficient to induce the appearance of a plethysmographic waveform signal at said means for sensing, to further reduce said occlusion by a degree sufficient to maximize the intensity of said plethysmographic waveform signal, and to still further reduce said occlusion until said plethysmographic waveform undergoes no further change.
57. The apparatus of claim 56, wherein said appearance of said plethysmographic waveform is indicative of systolic pressure of said pulsatile vascular compartment, said maximum signal intensity of said plethysmographic signal is indicative of mean pressure of said pulsatile vascular compartment, and said point at which said plethysmographic waveform ceases to change is indicative of diastolic pressure of said pulsatile vascular compartment.
58. The apparatus of claim 57, wherein said means for selectively occluding comprises a cuff disposed about said patient body portion and inflatable to a pressure sufficient to occlude said pulsatile vascular compartment, and said indication of said systolic, mean and diastolic pressure of said pulsatile vascular compartment is correlated to the actual systolic, mean and diastolic pressures of said vascular compartment by pressure transducer means associated with said cuff, the output of which is converted by said processing means to said actual pressures.
59. The apparatus of claim 31, wherein said means far producing a constant current comprises means for producing said current at a plurality of said second high carrier wave frequencies.
60. The apparatus of claim 31, wherein said means for processing said at least two complex waveforms employs the magnitudes thereof to determine said hematocrit of said blood.
61. The apparatus of claim 31, wherein said means for processing said at least two complex waveforms employs the magnitudes and phases thereof to determine said hematocrit of said blood.
62. The apparatus of claim 31, wherein said first low cattier wave frequency lies at about 100 kHz, arid sand at least one second high carrier wave frequency lies between 100 kHz and about 10 MHz.
53. A method for noninvasive determination of the relative volume percent of erythrocytes, also termed the hematocrit, of blood having an impedance, comprising:
producing a constant current at a fixer low and at least one second high carrier wave frequencies, said first low frequency being below a frequency zone within which said erythrocytes significantly affect the magnitude of the impedance of sand blood, and said at least one second high frequency being within said frequency zone;
stimulating a patient body portion including at least one pulsatile vascular compartment containing said blood with said first low and said at least one second high frequency current;
sensing voltage signals at each of said first low and said at least one second high carrier wave frequencies across said stimulated patient body portion;
amplifying said sensed voltage signals;
demodulating said amplified, sensed voltage signals to produce at least two complex waveforms respectively proportional to the magnitude of impedance of said blood at said first low and said at least one second high carrier wave frequencies; and processing said at least two complex waveforms to determine said hematocrit of said blood.
64. The method of claim 63, further comprising producing said current at a plurality of said second high carrier wave frequencies.
65. The method of claim b3, wherein processing said at least two complex waveforms employs the magnitudes thereof to determine said hematocrit of said blood.
66. The method of claim 63, wherein processing said at least two complex waveforms employs the magnitudes and phases thereof to determine said hematocrit of said blood.
67. The method of claim 63, wherein said first low carrier wave frequency lies at about 100 kHz, and said at least one second high carrier wave frequency lies within the range from about 10 MHz to about 20 MHz.
68. The method of claim 63, wherein said first low carrier wave frequency lies at about 100 kHz, and said at least one second high carrier wave frequency lies between 100 kHz and about 10 MHz.
69. The method of claim 63, further comprising selectively occluding said pulsatile vascular compartment.
70. The method of claim 69, wherein said selective occlusion comprises partial occlusion.
71. The method of claim 69, wherein said selective occlusion comprises substantially total occlusion.
72. The method of claim 69, wherein said selective occlusion is effected by applying pressure about said pulsatile vascular compartment in the region of the mean pressure of said pulsatile vascular compartment.
73. The method of claim 69, wherein said selective occlusion is effected on said patient body portion proximate locations thereon wherein said stimulating and said sensing are performed.
74. ~The method of claim 63, wherein said patient body portion further includes at least one non-pulsatile vascular compartment, and said method further includes selectively occluding said at least one non-pulsatile vascular compartment while sand at least one pulsatile vascular compartment remains unoccluded.
75. ~The method of claim 63, further comprising compensating for non-homogeneous flow of said blood through said pulsatile vascular compartment in determining said hematocrit of said blood.
76. ~The method of claim 63, further comprising determining blood pressure of said blood in said pulsatile vascular compartment.
77. ~The method of claim 76, wherein said determining said blood pressure includes selectively occluding said pulsatile vascular compartment.
78. ~The method of claim 77, wherein said selective occlusion of said pulsatile vascular compartment for determination of blood pressure includes completely occluding said vascular compartment, subsequently reducing said complete occlusion by a degree sufficient to induce the appearance of a plethysmographic waveform signal, to further reduce said occlusion by a degree sufficient to maximize the intensity of said plethysmographic waveform signal, and to still further reduce said occlusion until said plethysmographic waveform undergoes no further change.
79. ~The method of claim 78, wherein said appearance of said plethysmographic waveform is indicative of systolic pressure of said pulsatile vascular compartment, said maximum signal intensity of said plethysmographic signal is indicative of mean pressure of said pulsatile vascular compartment, and said point at which said plethysmographic waveform ceases to change is indicative of diastolic pressure of sand pulsatile vascular compartment.
80. ~The method of claim 79, further including selectively occluding using a cuff disposed about said patient body portion and inflatable to a pressure sufficient to occlude said pulsatile vascular compartment, and said indication of said systolic, mean and diastolic pressure of said pulsatile vascular compartment is correlated to the actual systolic, mean and diastolic pressures of said vascular compartment by pressure transducer means associated with said cuff, the output of which is processed to said actual pressures.
81. The system of claim 23, wherein the first signals are current signals and the second signals are voltage signals.
CA002218281A1995-04-201996-04-03Method and apparatus for noninvasively determining hematocritExpired - Fee RelatedCA2218281C (en)

Applications Claiming Priority (7)

Application NumberPriority DateFiling DateTitle
US08/425,404US5526808A (en)1990-10-041995-04-20Method and apparatus for noninvasively determining hematocrit
US08/425,4041995-04-20
US48449095A1995-06-071995-06-07
US08/484,4901995-06-07
US08/602,700US5642734A (en)1990-10-041996-02-16Method and apparatus for noninvasively determining hematocrit
US08/602,7001996-02-16
PCT/US1996/004547WO1996032883A1 (en)1995-04-201996-04-03Method and apparatus for noninvasively determining hematocrit

Publications (2)

Publication NumberPublication Date
CA2218281A1 CA2218281A1 (en)1996-10-24
CA2218281Ctrue CA2218281C (en)2004-08-17

Family

ID=27411466

Family Applications (1)

Application NumberTitlePriority DateFiling Date
CA002218281AExpired - Fee RelatedCA2218281C (en)1995-04-201996-04-03Method and apparatus for noninvasively determining hematocrit

Country Status (6)

CountryLink
EP (1)EP0955871A4 (en)
JP (1)JP3844779B2 (en)
CN (1)CN1244779A (en)
AU (1)AU5383796A (en)
CA (1)CA2218281C (en)
WO (1)WO1996032883A1 (en)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US6766191B1 (en)1990-10-042004-07-20Microcor, Inc.System and method for in-vivo hematocrit measurement using impedance and pressure plethysmography
ES2143911B1 (en)*1997-03-062000-12-01Nte Sa METHOD AND APPARATUS FOR MEASURING THE CONCENTRATION AND COMPOSITION OF BIOMASS.
AU762922B2 (en)*1998-02-042003-07-10Dermal Therapy (Barbados) Inc.Method and apparatus for non-invasive determination of glucose in body fluids
AU2001261847A1 (en)*2000-05-162001-11-26Microcor, Inc.System and method for in-vivo hematocrit measurement using impedance and pressure plethysmography
US7228170B2 (en)2000-08-142007-06-05Renal Research Institute, LlcDevice and method for monitoring and controlling physiologic parameters of a dialysis patient using segmental bioimpedance
US6615077B1 (en)2000-08-142003-09-02Renal Research Institute, LlcDevice and method for monitoring and controlling physiologic parameters of a dialysis patient using segmental bioimpedence
WO2004086940A2 (en)2003-03-252004-10-14Fresenius Medical Care Holdings, Inc.Device and method for performing electrical impedance tomography
WO2004098376A2 (en)*2003-05-122004-11-18Cheetah Medical Inc.System, method and apparatus for measuring blood flow and blood volume
CN100457021C (en)*2003-06-032009-02-04奥森斯有限公司Method and system for use in non-invasive optical measurements of blood parameters
EP1707953B1 (en)*2003-12-042015-07-01Panasonic Healthcare Holdings Co., Ltd.Method of measuring hematocrit (Hct)
CN100472210C (en)2003-12-042009-03-25松下电器产业株式会社 Method for measuring blood components and sensor and measuring device used in the method
EP3115777B1 (en)2004-04-192020-01-08PHC Holdings CorporationMethod for measuring blood components
US7356366B2 (en)2004-08-022008-04-08Cardiac Pacemakers, Inc.Device for monitoring fluid status
WO2006087696A2 (en)2005-02-152006-08-24Cheetah Medical Ltd.System, method and apparatus for measuring blood flow and blood volume
EP1954175B1 (en)2005-11-102016-07-13Biovotion AGDevice for determining the glucose level in body tissue
JP4640608B2 (en)*2005-12-122011-03-02ソニー株式会社 Detection apparatus and detection method
JP5071768B2 (en)*2006-12-082012-11-14学校法人日本大学 Blood flow velocity measuring device
JP5071767B2 (en)*2006-12-082012-11-14学校法人日本大学 Biological tissue blood flow measurement device
US9095271B2 (en)2007-08-132015-08-04Cheetah Medical, Inc.Dynamically variable filter
US8876725B2 (en)2007-02-232014-11-04Cheetah Medical, Inc.Method and system for estimating exercise capacity
US8764667B2 (en)2007-03-072014-07-01Cheetah Medical, Inc.Method and system for monitoring sleep
US8523777B2 (en)2007-04-192013-09-03Cheetah Medical, Inc.Method, apparatus and system for predicting electromechanical dissociation
US8168063B2 (en)2008-07-092012-05-01Baxter International Inc.Dialysis system having filtering method for determining therapy prescriptions
US8062513B2 (en)2008-07-092011-11-22Baxter International Inc.Dialysis system and machine having therapy prescription recall
US8057679B2 (en)2008-07-092011-11-15Baxter International Inc.Dialysis system having trending and alert generation
US7981281B2 (en)2008-07-092011-07-19Baxter International, Inc.Dialysis system having regimen generation methodology
US9514283B2 (en)2008-07-092016-12-06Baxter International Inc.Dialysis system having inventory management including online dextrose mixing
DK2346395T3 (en)*2008-09-222018-06-06Cheetah Medical Inc SYSTEM AND PROCEDURE FOR DETERMINING BLOOD FLOW
RU2395086C1 (en)*2008-11-242010-07-20Государственное образовательное учреждение высшего профессионального образования Самарский государственный аэрокосмический университет имени академика С.П. КоролеваDevice for determining indicant of hematocrit
JP5628289B2 (en)2009-04-172014-11-19バイオボーション・アーゲーBiovotion AG Broadband field response measurement for glucose determination
US8282829B2 (en)2009-05-202012-10-09Baxter International Inc.System and method for automated data collection of twenty-four hour ultrafiltration and other patient parameters using wired or wireless technology
US8926551B2 (en)2009-07-072015-01-06Baxter Healthcare Inc.Peritoneal dialysis therapy with large dialysis solution volumes
JP2011078443A (en)*2009-10-022011-04-21Tanita CorpBiometric measurement apparatus
ES2656222T3 (en)*2011-02-172018-02-26Qualcomm Incorporated A procedure and a system for determining a cardiovascular magnitude of a mammal
CN102694509B (en)*2011-03-222017-02-15北京汉朔科技有限公司An integrated electro-physiological signal amplifier with an AC excitation function
JP5726662B2 (en)*2011-07-222015-06-03学校法人上智学院 Blood impedance measuring device, artificial dialysis device, and method for operating blood impedance measuring device
KR102209543B1 (en)2011-07-252021-01-29치타 메디컬, 인코퍼레이티드Method and system for monitoring hemodynamics
US8623660B2 (en)*2011-09-302014-01-07Lifescan Scotland LimitedHand-held test meter with phase-shift-based hematocrit measurement circuit
CN103149132B (en)*2013-03-182015-02-25深圳市理邦精密仪器股份有限公司Detection system for improving accuracy of measuring packed cell volume accuracy and operating control method
US20150196224A1 (en)*2014-01-162015-07-16Dermal Therapy (Barbados) Inc.Implantable Sensor and Method for Such Sensor
CA2947000C (en)2014-05-232018-12-11Nova Biomedical CorporationHemolysis detection method and system
CN105403691B (en)*2016-01-012017-08-18赛奥生物科技(青岛)有限公司A kind of Blood Kit analysis system
US11568990B2 (en)*2016-11-212023-01-31Sensome SASCharacterizing and identifying biological structure
CA3069303C (en)*2017-07-112024-06-18Fresenius Medical Care Holdings, Inc.Techniques for determining fluid volumes using bioimpedance information
JP6895876B2 (en)*2017-12-132021-06-30アークレイ株式会社 Measuring method and measuring device to measure hematocrit value in blood
WO2020232706A1 (en)*2019-05-232020-11-26麦层移动健康管理有限公司Method and device for measuring body fluid and its changes and for measuring blood flow changes

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US3994284A (en)*1975-12-311976-11-30Systron Donner CorporationFlow rate computer adjunct for use with an impedance plethysmograph and method
US4425920A (en)*1980-10-241984-01-17Purdue Research FoundationApparatus and method for measurement and control of blood pressure
DE3202067C2 (en)*1982-01-231984-06-20Holger Dr. 5100 Aachen Kiesewetter Device for determining the hematocrit value
SE455043B (en)*1982-04-221988-06-20Karolinska Inst DEVICE FOR MONITORING THE LIQUID BALANCE OF THE HUMAN BODY BY MEASURING THE IMPEDANCE OF THE BODY
JP2665806B2 (en)*1989-09-131997-10-22株式会社豊田中央研究所 Hematocrit measuring device
US5404879A (en)*1993-01-191995-04-11Hewlett-PackardMethod and apparatus for automatic non-invasive monitoring of a patient's blood pressure
JP3345481B2 (en)*1993-09-222002-11-18興和株式会社 Pulse wave spectrometer

Also Published As

Publication numberPublication date
JP2001500392A (en)2001-01-16
EP0955871A4 (en)2000-03-22
EP0955871A1 (en)1999-11-17
CN1244779A (en)2000-02-16
JP3844779B2 (en)2006-11-15
WO1996032883A1 (en)1996-10-24
AU5383796A (en)1996-11-07
CA2218281A1 (en)1996-10-24

Similar Documents

PublicationPublication DateTitle
CA2218281C (en)Method and apparatus for noninvasively determining hematocrit
US5642734A (en)Method and apparatus for noninvasively determining hematocrit
US5526808A (en)Method and apparatus for noninvasively determining hematocrit
US8068906B2 (en)Cardiac monitoring system
CA2186686C (en)Method and device for determining brachial arterial pressure wave on the basis of noninvasively measured finger blood pressure wave
US6616613B1 (en)Physiological signal monitoring system
US7468037B2 (en)Apparatus and method for measuring hemodynamic parameters
US20090082679A1 (en)Cardiac monitoring system
US20060247543A1 (en)High resoution bio-impedance device
US7011631B2 (en)Noninvasive method of measuring blood density and hematocrit
US20120065523A1 (en)Dvt detection
Schneider et al.An approach to improve impedance plethysmography on the wrist by using adaptive feedback control
ZA200106578B (en)Method and device for continuous analysis of cardiovascular activity of a subject.
EP2281504A1 (en)Apparatus and method for determining a physiological parameter
Arenson et al.Dual-channel self-balancing impedance plethysmograph for vascular studies
KR102438217B1 (en)Cardiac output measuring device using reactance component and weight scale including same
CN112990029A (en)Method for evaluating venous vessel state

Legal Events

DateCodeTitleDescription
EEERExamination request
MKLALapsed

Effective date:20130403


[8]ページ先頭

©2009-2025 Movatter.jp